| Autor: |
Akhverdyan N; University of Colorado School of Medicine, Aurora, Colorado, USA., Wieland A; Division of Hepatology, University of Colorado School of Medicine, Aurora, Colorado, USA., Sullivan S; Division of Gastroenterology, University of Colorado School of Medicine, Aurora, Colorado, USA., Lindsay M; Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, USA., Swartwood S; Division of Hepatology, University of Colorado School of Medicine, Aurora, Colorado, USA., Arndt G; Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, USA., Kaizer LK; Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Jensen T; Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Metabolic syndrome and related disorders [Metab Syndr Relat Disord] 2024 Oct; Vol. 22 (8), pp. 608-618. Date of Electronic Publication: 2024 Jun 13. |
| DOI: |
10.1089/met.2024.0115 |
| Abstrakt: |
Introduction: Current guidelines recommend the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), especially in patients with comorbid diabetes and obesity. This study investigated the effects of GLP-1RAs on hepatic steatosis and fibrosis in patients with MASLD, as measured by changes in vibration-controlled transient elastography (VCTE) and other clinical parameters in a real-world clinical setting. Methods: We conducted a single-center, retrospective analysis of 96 patients with MASLD from a multidisciplinary care clinic who completed VCTE at baseline and follow-up within 6-24 months to compare changes in controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), as well as other metabolic markers, between GLP-1RA users and nonusers using two-sample t -tests and Wilcoxon rank-sum tests. We also assessed whether improvements in hepatic steatosis, defined as a change in CAP >38 dB/m as previously described in the literature, were associated with improvement in fibrosis. Results: GLP-1RA use resulted in significant improvements in weight (-8.1 kg vs. -3.5 kg, P = 0.009), body mass index (BMI) (-2.9 kg/m 2 vs. -1.3 kg/m 2 , P = 0.012), alanine aminotransferase (-15.0 IU/L vs. -4.0 IU/L, P = 0.017), aspartate aminotransferase (-5.0 IU/L vs. -1.0 IU/L, P = 0.021), glycated hemoglobin (HbA1c) (-0.7% vs. 0.1%, P = 0.019), and CAP (-59.9 dB/m vs. -29.1 dB/m, P = 0.016). Responders also had significant improvements in weight (-9.2 kg vs. -1.9 kg, P < 0.001), BMI (-3.3 kg/m 2 vs. -0.7 kg/m 2 , P < 0.001), diastolic blood pressure (-6.1 mmHg vs. -0.7 mmHg, P = 0.028), HbA1c (-0.8% vs. 0.3%, P < 0.001), and LSM (-1.5 kPa vs. 0.1 kPa, P < 0.001). Conclusions: Patients with MASLD treated with GLP-1RAs showed significant improvements in hepatic steatosis and multiple other metabolic parameters, with weight loss as the proposed mechanism for this liver improvement. In addition, change in CAP >38 dB/m was associated with improvements in LSM and other metabolic parameters, suggesting the clinical utility of VCTE in the surveillance of MASLD. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
